Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

103.20EUR
11:34am EST
Change (% chg)

€0.45 (+0.44%)
Prev Close
€102.75
Open
€102.50
Day's High
€103.25
Day's Low
€102.15
Volume
620,156
Avg. Vol
417,779
52-wk High
€103.95
52-wk Low
€71.15

MRCG.DE

Chart for MRCG.DE

About

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnol... (more)

Overall

Beta: 1.03
Market Cap(Mil.): €13,279.64
Shares Outstanding(Mil.): 129.24
Dividend: 1.05
Yield (%): 1.02

Financials

  MRCG.DE Industry Sector
P/E (TTM): 30.17 28.90 29.71
EPS (TTM): 3.41 -- --
ROI: 5.40 13.43 12.94
ROE: 11.01 14.33 14.09

BRIEF-Ablynx's partner Merck reports encouraging results with nanobody

* Ablynx's partner, Merck KGaA, reports encouraging results with the bi-specific nanobody anti-il-17a/f (m1095) in a phase ib clinical study in patients with psoriasis

Jan 26 2017

BRIEF-Merck KGaA, Darmstadt, Germany, announces research collaboration with Domain Therapeutics in immuno-oncology

* Merck kgaa, darmstadt, germany, announces research collaboration with domain therapeutics in immuno-oncology

Jan 23 2017

BRIEF-Merck Kgaa, Darmstadt, Germany, Palantir launch new healthcare partnership

* Merck KGAA - Merck KGAA, Darmstadt, Germany, and Palantir launch new healthcare acceleration partnership

Jan 12 2017

BRIEF-Merck and CLEARink Displays sign development agreement

* Signs a comprehensive materials development agreement with CLEARink Displays, Inc., aiming to bring CLEARink's innovative and patented reflective display technology to market by end of 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 10 2017

German Merck, Pfizer get FDA priority review for cancer drug

FRANKFURT German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek approval to fight a rare and aggressive form of skin cancer with immunotherapy drug avelumab.

Nov 29 2016

German Merck, Pfizer get FDA priority review for cancer drug

FRANKFURT, Nov 29 German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek approval to fight a rare and aggressive form of skin cancer with immunotherapy drug avelumab.

Nov 29 2016

BRIEF-QuintilesIMS forms new Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe

* Quintilesims forms new collaboration with Bristol-Myers Squibb, Lilly, Merck Kgaa, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe Source text for Eikon: Further company coverage:

Nov 22 2016

UPDATE 1-Merck KGaA expects profit gain from lower development costs

* Shares rise 3 pct in early Frankfurt trade (Adds details on reasons for higher guidance, fertility treatment)

Nov 15 2016

Merck KGaA lifts profit guidance on lower development costs

FRANKFURT, Nov 15 German drugs and lab supplies maker Merck KGaA lifted its full-year profit forecast on lower drug development costs.

Nov 15 2016

BRIEF-Merck KGaA says primary endpoint was not met in study population

* Merck KGaA - primary endpoint was not met in overall study population

Nov 14 2016

More From Around the Web

Earnings vs. Estimates